SMM-Chemokines: A Class of Unnatural Synthetic Molecules as Chemical Probes of Chemokine Receptor Biology and Leads for Therapeutic Development  by Kumar, Santosh et al.
Chemistry & Biology 13, 69–79, January 2006 ª2006 Elsevier Ltd All rights reserved DOI 10.1016/j.chembiol.2005.10.012SMM-Chemokines: A Class of Unnatural Synthetic
Molecules as Chemical Probes of Chemokine
Receptor Biology and Leads for Therapeutic
DevelopmentSantosh Kumar,1,6 Won-Tak Choi,1,6
Chang-Zhi Dong,1,6 Navid Madani,3 Shaomin Tian,1
Dongxiang Liu,1 Youli Wang,1 James Pesavento,1
Jun Wang,1 Xuejun Fan,1 Jian Yuan,1
Wayne R. Fritzsche,5 Jing An,1,5 Joseph G. Sodroski,3
Douglas D. Richman,4 and Ziwei Huang1,2,*
1Department of Biochemistry
2Department of Chemistry
University of Illinois at Urbana-Champaign
Urbana, Illinois 61801
3Department of Cancer Immunology and AIDS
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts 02115
4Department of Molecular Pathology
Center for AIDS Research
University of California, San Diego
La Jolla, California 92093
5Raylight Corporation
Chemokine Pharmaceutical Inc.
10931 North Torrey Pines Road
La Jolla, California 92037
Summary
Chemokines and their receptors play important roles
in numerous physiological and pathological pro-
cesses. To develop natural chemokines into receptor
probes and inhibitors of pathological processes, the
lack of chemokine-receptor selectivity must be over-
come. Here, we apply chemical synthesis and the con-
cept of modular modifications to generate unnatural
synthetically and modularly modified (SMM)-chemo-
kines that have high receptor selectivity and affinity,
and reduced toxicity. A proof of the concept was
shown by transforming the nonselective viral macro-
phage inflammatory protein-II into new analogs with
enhanced selectivity and potency for CXCR4 or
CCR5, two principal coreceptors for human immuno-
deficiency virus (HIV)-1 entry. These new analogs pro-
vided insights into receptor binding and signaling
mechanisms and acted as potent HIV-1 inhibitors.
These results support the concept of SMM-chemo-
kines for studying and controlling the function of other
chemokine receptors.
Introduction
Chemokine receptors belong to the superfamily of
G protein-coupled receptors (GPCRs). As the natural
ligands of chemokine receptors, chemokines can be di-
vided into four subfamilies based on the positions of two
conserved cysteine residues in their amino (N)-termini:
*Correspondence: ziweihuang@burnham.org
6 These authors contributed equally to this work.CC, CXC, CX3C, and C. Chemokines act as chemo-
attractants of various types of leukocytes to sites of
inflammation and to secondary lymphoid organs. Che-
mokines and their receptors are also involved in neuro-
logical disorders, cancer, and, most notably, acquired
immune deficiency syndrome (AIDS) [1–4]. Two principal
coreceptors, CXCR4 and CCR5, are required for human
immunodeficiency virus (HIV)-1 entry [5–8]. During the
asymptomatic stage of disease, M-tropic strains of
HIV-1 primarily use CCR5 as an entry coreceptor [9–11].
However, in 40%–50% of HIV-1-infected individuals,
T-tropic strains that predominantly use CXCR4 eventu-
ally replace M-tropic strains, leading to rapid disease
progression [12–14]. Natural chemokines of CXCR4 or
CCR5 can inhibit HIV-1 infection [15, 16] by blocking
gp120 binding sites on CXCR4 or CCR5 [17, 18] and/or
by inducing receptor internalization [19, 20].
Despite many important roles of chemokines and their
receptors in numerous physiological and pathological
processes, a challenge to the field of chemokine biology
is the search for specific inhibitors of the chemokine
system, given that 50 chemokine ligands and 19 func-
tional receptors have been described to date [4]. The
lack of selectivity among chemokine ligands is exempli-
fied by viral macrophage inflammatory protein (vMIP)-II,
which recognizes a variety of CC and CXC chemokine
receptors, including CXCR4, CCR5, and CCR2 [21].
Although the potential benefits of chemokine receptor
inhibitors for AIDS and other diseases have been dem-
onstrated, the lack of selectivity in the chemokine sys-
tem has made it problematic to use natural chemokines
or nonspecific, synthetic inhibitors in clinical applica-
tions due to their potential side effects. For instance,
there is cause for concern regarding undesired side
effects of blocking the normal CXCR4 function, since
knockout mice lacking either CXCR4 [22, 23] or its only
natural ligand, stromal cell-derived factor (SDF)-1a
[24], die during embryogenesis, with evidence of hema-
topoietic, cardiac, vascular, and cerebellar defects.
Consequently, the development of new inhibitors engi-
neered with higher selectivity for specific regions of
CXCR4 that are selective for HIV-1 coreceptor function
only, but not the normal function of SDF-1a, is clearly de-
sirable. In fact, we have recently reported potentially dif-
ferent determinants for CXCR4 interactions with HIV-1
gp120 and SDF-1a, which provided a basis for the devel-
opment of new inhibitory agents that modulate the func-
tional sites or conformations of CXCR4 for the purpose
of reducing or avoiding the limitations and side effects
caused by nonselective inhibitors of this important co-
receptor [25].
There has been intensive work in the development of
new chemokine analogs by other groups in the field.
For instance, Clark-Lewis and his colleagues have ex-
tensively studied the structure-function relationship of
interleukin 8 and other chemokine receptors using
chemically synthesized chemokine analogs [26–28]. On
the basis of these previous works by others, we have
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strategy based on chemokine structures to synthesize
a new family of unnatural chemokines that, unlike natu-
ral chemokines, have higher receptor binding selectivity.
Here, we report our recent progress in developing such
a strategy by employing synthetically and modularly
modified (SMM)-chemokines as a potential method for
the de novo design of novel ligands selective for any
chemokine receptor of interest. For this approach, the
word ‘‘synthetically’’ refers to the use of total chemical
synthesis to incorporate an almost unlimited range of
unnatural amino acids and chemical modifications at
any specific site(s). The word ‘‘modularly’’ refers to the
changes of short, important sequence modules, rather
than the entire sequences, to achieve efficiency and be
cost-effective in the generation of specificity and diver-
sity. The word ‘‘modified’’ refers to the ability through
various chemical modifications to improve biological
properties (e.g., low toxicity and high receptor selectiv-
ity and affinity) that are more desirable in clinical appli-
cations and basic research of receptor biology. We
show how this SMM-chemokine approach can be
applied to convert the nonselective vMIP-II into highly
selective ligands for CXCR4 or CCR5 with desirable
binding, signaling, antiviral, internalization, and toxicity
profiles. The general implications of such a chemical bi-
ology approach for studying chemokine receptor biol-
ogy and addressing critical medical issues, such as
the drug resistance in AIDS treatment, are discussed.
Results
General Design Concept and Chemical Synthesis
of SMM-Chemokines Based on vMIP-II
We wanted to demonstrate the concept and feasibility of
SMM-chemokine strategy in addressing the issue of
lack of selectivity in natural chemokine-receptor inter-
actions and generating unnatural ligands with designed
receptor selectivity and improved pharmacological pro-
files. vMIP-II, designated here as RCP111, was chosen
as the target molecule, as it binds a wide range of che-
mokine receptors including CXC and CC receptor sub-
families [21]. We focused on CXCR4 and CCR5 as two
representative receptors in CXC and CC subfamilies, re-
spectively, for the reason that these two receptors are
the principal coreceptors in HIV-1 entry. As an additional
control, CCR2 was used to test the specificity of our
vMIP-II-derived SMM-chemokines. Our goal was to ap-
ply the SMM-chemokine approach to overcome the
nonselectivity of vMIP-II and generate highly specific
analogs of CXCR4 or CCR5.
The structures of several chemokines that bind
CXCR4 or CCR5 have been determined by NMR or
X-ray techniques, including those of MIP-1b [29], regu-
lated on activation, normal T cell expressed and se-
creted (RANTES) [30], SDF-1a [27, 31], and vMIP-II [32,
33]. Based on these structures, the structure and func-
tion relationship of these chemokines has been investi-
gated mainly by a chemical approach of synthetic che-
mokine mutants and peptides. For instance, two
groups showed, by using synthetic peptides, that the
N terminus of SDF-1a is important for CXCR4 binding
and signaling [27, 34]. By synthesizing a series of pepti-
des derived from different regions of the full-length se-quence, we also found that the N terminus of vMIP-II is
the major determinant for CXCR4 binding [35–37]. Fi-
nally, the importance of the N terminus was demon-
strated by our synthetic N terminus-truncated vMIP-II
(RCP112) that had the deletion of residues 1–10 and
showed a significant loss in its binding activity to
CXCR4, CCR5, and CCR2 (Tables 1 and 2).
Because the N terminus is a key determinant of recep-
tor binding affinity, selectivity, and signaling activity for
many chemokines, including vMIP-II [27, 28, 34, 35,
37–40], we modified the N-terminal (1–10) sequence
module of vMIP-II by introducing unnatural D-amino
acids or specific sequences grafted from other chemo-
kines to achieve our goal of overcoming the nonselectiv-
ity of vMIP-II and generating specific analogs of CXCR4
or CCR5 (Figure 1A). We designed a panel of SMM-
chemokines containing D-amino acids or other se-
quence modifications at this module and studied their
different affinities and selectivity for CXCR4, CCR5,
and CCR2. The chemical preparation yielded these mol-
ecules in high purity and correct identity, as shown by
the HPLC and MALDI-MS data of vMIP-II as a represen-
tative example (Figures 1B and 1C). The CD spectros-
copy also indicated that SMM-chemokines display
similar patterns on the CD spectra to their parent tem-
plate, vMIP-II, demonstrating that the modifications at
the N terminus have little effect on the overall conforma-
tion of the vMIP-II core structure (Figure 1D). The con-
servation of the core structure among the designed
SMM-chemokines described here is further demon-
strated by the high-resolution crystal structure of
D(1–10)-vMIP-II (RCP168, Table 1), which displays a sim-
ilar conformation in the core template region as that of
RCP111 (unpublished data).
Design of SMM-Chemokines that Bind CXCR4
with High Selectivity and Affinity
To convert the nonselective RCP111 into highly selec-
tive SMM-chemokines for CXCR4, we synthesized
RCP168 (Table 1) containing D-amino acids at its N ter-
minus. The rationale for introducing D-amino acids at
the N-terminal (1–10) sequence module was based on
our recent discovery that D-peptides derived from this
module of vMIP-II display high binding selectivity for
CXCR4, but not for CCR5 [37]. Thus, we reasoned that
the incorporation of D-amino acids at the N terminus
of the full-length molecule might also endow the new an-
alog with enhanced selectivity and affinity for CXCR4.
Indeed, the CXCR4 binding activity of RCP168 (IC50 =
5 nM) was over four times greater than that of RCP111
(IC50 = 22 nM) (Figure 2A; Table 2). As a negative control,
RCP112 in which the N-terminal (1–10) residues of vMIP-
II were deleted had a drastic loss in CXCR4 binding, as
a plateau of nonspecific binding could not be reached
even at 2.7 mM RCP112.
To test whether RCP168 is specific against other che-
mokine receptors, its binding activity was tested in
CCR5 competition binding assays (Figure 2B; Table 2).
In these assays, the positive control RCP111 showed
very high binding activity for CCR5 (IC50 = 4 nM),
whereas the negative control RCP112 had a loss in
CCR5 binding affinity of almost 40-fold compared with
that of RCP111. RCP168 was over 10 times less potent
than RCP111 in its binding to CCR5, which was in sharp
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.contrast to the significant CXCR4 binding enhancement
of RCP168. The decrease (10-fold) in CCR5 binding of
RCP168 coupled with its increase (4.4-fold) in CXCR4
binding led to a drastically improved selectivity of
RCP168 for CXCR4. The selectivity of RCP168 was fur-
ther demonstrated by CCR2 competition binding assays
(Figure 2C; Table 2). Again, the positive control RCP111
bound CCR2 with high affinity (IC50 = 33 nM), which is in
agreement with the other previous results [41, 42]. How-
ever, as observed in the CCR5 binding assays, RCP168
showed about a 16-fold decrease in CCR2 binding
(IC50 = 513 nM) compared with RCP111. These results
show that RCP168 is a selective and high-affinity ligand
of CXCR4.
Another CXCR4-selective ligand that differed slightly
from RCP168 was D(1–8)-GG-vMIP-II (RCP169). The
major difference between RCP169 and RCP168 was
that, in RCP169, two glycine residues were incorporated
to replace the residues 9 and 10 of RCP168, with the aim
of allowing more structural flexibility for the first eight D-
amino acid residues. Interestingly, RCP169 completely
lost its binding activity to CCR5 and CCR2, and yet re-
tained much of its binding affinity for CXCR4 (Figure 2;
Table 2). Residues 9 and 10 may play a more important
role in binding CCR5 and CCR2, as the mutations of
these residues to glycine residues led to almost com-
plete loss of CCR5 and CCR2 binding. Alternatively,
the conformational flexibility presumably introduced
by the glycine residues may be more disruptive for the
interactions with CCR5 and CCR2 than for those with
CXCR4. In either case, the data on RCP169 support
our design notion that D-amino acid modifications at
the N-terminal module can generate highly selective
analogs for CXCR4.
Design of SMM-Chemokines that Bind CCR5
with High Selectivity and Affinity
Following the development of highly selective CXCR4
ligands, we set out to design CCR5-specific SMM-
chemokines. However, we did not use the D-amino
acid modification strategy because it did not enhance
CCR5 binding affinity. Instead, we decided to replace
the N terminus of vMIP-II with that from another chemo-
kine known to bind CCR5 but not CXCR4 and/or other
receptors, with the aim that such a ‘‘foreign N terminus’’
might import the desired differentiating ability in recep-
tor binding (Table 1). For this reason, the N terminus (res-
idues 1–10) of MIP-1b, a CC subfamily chemokine that is
Table 2. Binding Affinity and Selectivity of SMM-Chemokines for
CXCR4, CCR, and CCR2
Analog
CXCR4
Binding (nM)
CCR5
Binding (nM)
CCR2
Binding (nM)
RCP111 22 4 33
RCP112 >2700 146 104
RCP168 5 43 513
RCP169 141 >2700 >2700
RCP188 >2700 6 107
RCP189 >2700 106 >2700
The binding activity of each SMM-chemokine is shown by its IC50
value, determined by competition receptor binding assays using
either labeled chemokines or receptor-specific antibodies.
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(A) The N-terminal (1–10) sequence module of vMIP-II was modified by introducing unnatural D-amino acids or specific sequences grafted
from other chemokines to chemically engineer receptor selectivity and/or signaling property.
(B and C) The HPLC (B) and MALDI-MS (C) of vMIP-II prepared by total chemical synthesis are shown as a representative example.
(D) SMM-chemokines and vMIP-II have similar patterns on the CD spectra.relatively specific for CCR5 [43], was grafted to replace
the N terminus of vMIP-II. The resulting synthetic mole-
cule, (1–10)-MIP-1b-(11–71)-vMIP-II (RCP188), showed
very strong binding activity to CCR5 (IC50 = 6 nM), but
its binding affinity was much weaker in binding CCR2
(by 18-fold) and totally inactive in binding CXCR4 (Fig-ure 2; Table 2). These results demonstrate the selectivity
of RCP188 for CCR5.
Signaling Activities of SMM-Chemokines
We conducted biochemical studies on the signaling ac-
tivities of CXCR4- or CCR5-specific SMM-chemokines.Figure 2. Binding Activities of SMM-Chemokines for CXCR4, CCR5, and CCR2
(A) 125I-SDF-1a competition binding assays.
(B) 125I-MIP-1b competition binding assays.
(C) a-CCR2 competition binding assays.
All data are shown as mean 6 SD from at least three independent experiments.
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(A) Ca2+ influx in Sup T1 cells was measured in response to 0 nM, 100 nM, and 1 mM RCP111, which was followed by adding 100 nM SDF-1a.
(B) The changes in [Ca2+]i of Sup T1 cells in response to RCP168 were measured. After 5 min of incubation, 100 nM SDF-1a was added.
(C) The Ca2+ signals induced by RCP188 in CCR5-transfected 293 cells were followed by 100 nM MIP-1b.
All the data shown are representative of at least three independent experiments.RCP111 at 100 nM or up to 1 mM did not induce any mo-
bilization of calcium (Ca2+) in Sup T1 cells expressing
CXCR4, which is in contrast to the rapid Ca2+ mobiliza-
tion induced by the normal CXCR4 ligand, SDF-1a
(Figure 3A). Whether RCP111 may interfere with the nor-
mal Ca2+ signaling activated by SDF-1a was also exam-
ined by adding 100 nM SDF-1a after treating Sup T1 cells
with RCP111. RCP111, despite its strong binding to
CXCR4, did not interfere with the Ca2+ mobilization in-
duced by SDF-1a, even at 100 nM, and only showed
a weak inhibitory effect when its concentration was in-
creased to 1 mM. Similarly, RCP168, which binds
CXCR4 with very high affinity, did not induce Ca2+ mobi-
lization at either 100 nM or even 1 mM. Moreover, it did
not interfere with the Ca2+ influx induced by SDF-1a until
at much higher concentrations, either 100 nM or 1 mM
(Figure 3B). As for the CCR5-specific ligand, RCP188,
the incorporation of the N terminus from MIP-1b, which
is a CCR5 agonist, enabled RCP188 to elicit Ca2+ release
in CCR5-transfected 293 cells at sufficiently high con-
centrations, such as 1 mM (Figure 3C). At 1 mM,
RCP188 also interfered with the Ca2+ mobilization in-
duced by 100 nM MIP-1b. In control experiments,
RCP188 neither triggered Ca2+ release nor interfered
with SDF-1a signaling in Sup T1 cells (data not shown),
which is consistent with the binding data showing that
RCP188 is a selective CCR5 ligand.
Potent Anti-HIV Activities of SMM-Chemokines
We performed antiviral experiments to investigate
whether SMM-chemokines, such as RCP168, with en-
hanced receptor binding affinity can be used as potential
intervening agents for diseases, such as HIV-1 entry
and infection mediated by CXCR4. Among the SMM-
chemokines listed in Table 1, RCP168 was chosen as the
representative compound to be tested for inhibition of
HIV-1 infection via CXCR4. As shown in Figure 4A, the an-
tiviral activity of RCP168 was comparable to 30-azodi-
thymidine or zidovudine (AZT) and nevirapine (NVP),
which are nucleoside (NRTI) and nonnucleoside reverse-
transcriptase inhibitors (NNRTI), respectively, and com-monly used drugs in the clinical treatment of AIDS.
Since RCP168 blocks the viral entry pathway that differs
from the viral replication step targeted by AZT and
many other anti-HIV drugs, it can be expected that mol-
ecules like RCP168 may be able to overcome the drug
resistance problem encountered by AZT and other
anti-HIV drugs in the resistant viral isolates. To test these
hypotheses, we assayed RCP168 against several dif-
ferent viral isolates known to be resistant to reverse-
transcriptase inhibitors. Whereas RCP168 displayed
similar potency to AZT and NVP against a wild-type
virus (NL4-3, Figure 4A), reverse-transcriptase inhib-
itors consistently displayed reduced activity com-
pared with RCP168 against the drug resistant viruses
(Figures 4B–4E).
Internalization Activities of CXCR4-Targeting
SMM-Chemokines
An important biological activity of SDF-1a is its ability to
cause CXCR4 internalization [19, 20], which is sug-
gested to be one mechanism for its anti-HIV activity. In
this regard, RCP168 was tested in internalization assays
in an effort to examine its mechanism of action. Unlike
SDF-1a, which induced 50% receptor loss when its con-
centration was increased up to 1 mM, RCP168, with con-
centrations ranging from 0.1 nM to 1 mM, failed to cause
CXCR4 downregulation (Figure 5A). The impact of time
was also examined. As shown in Figure 5B, neither
RCP168 nor RCP111 elicited any significant internaliza-
tion of CXCR4, even after 90 min of incubation. In con-
trast, SDF-1a induced rapid receptor downregulation,
as 50% of the receptors were internalized after 30 min
of incubation. These results suggest that RCP168 inhib-
its HIV-1 entry through the direct blockade of HIV-1
gp120 binding to CXCR4, rather than causing a decrease
in the number of CXCR4 on the cell surface. This feature
of RCP168 is desirable, since CXCR4 signal activation
and downregulation are considered side effects and
should be avoided when using an inhibitor of HIV-1 entry
in clinical applications.
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kines
The antiviral activity of RCP168 was assayed
against a panel of HIV-1 strains resistant to
approved reverse-transcriptase inhibitors.
The strains and their corresponding mu-
tations in reverse transcriptase are: (A) NL
4-3 (wild-type); (B) G910-6 (M41L, D67N,
K70R, T215Y, L219G); (C) H292-1 (being se-
quenced); (D) M558-2 (being sequenced);
and (E) S531 (M184).Toxicities of SMM-Chemokines
In addition to the issue of receptor activation for natural
chemokines such as SDF-1a, the cross binding of natu-
ral chemokines to receptors other than the targeted one
can lead to side effects including toxic effects on unin-
fected cells. To illustrate this point and demonstrate
the advantages of SMM-chemokines over natural che-
mokines, cytotoxicity assays were performed usingCellTiter 96 aqueous nonradioactive cell proliferation
assays. The conversion of a tetrazolium compound (3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) into
soluble formazan is accomplished by dehydrogenase
enzymes found only in metabolically active cells. Thus,
the quantity of formazan product (solubilized MTS), as
measured by the absorbance at 490 nm, is directlyFigure 5. Receptor Internalization Activities
and Cytotoxicities of SMM-Chemokines
(A) An increase in the concentration of
RCP168 from 0.1 nM to 1 mM failed to cause
CXCR4 downregulation, while 1 mM SDF-1a
induced 50% receptor loss.
(B) The longer incubation of cells with either
RCP168 or RCP111 did not elicit any signifi-
cant internalization of CXCR4.
(C) The toxicity of 100 mM RCP168 was
examined using CellTiter 96 aqueous nonra-
dioactive cell proliferation assays. RCP168
showed no obvious cellular toxicity, whereas
the natural chemokine, RCP111, showed
a significant cellular toxicity.
All the data shown are representative of at
least three independent experiments.
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natural chemokine, RCP111, which is known to be non-
selective in recognizing many chemokine receptors,
showed a significant toxic effect on white blood cells
(WBCs), with 40% cell death after 24 hr incubation
(Figure 5C). In contrast, RCP168, which is chemically en-
gineered with high receptor selectivity, showed little ef-
fect on the cell viability even at 100 mM, a much higher
concentration than is required for the inhibition of
HIV-1. These data support the notion that SMM-chemo-
kines like RCP168 may have fewer side effects and be
more advantageous than the natural chemokines for
potential clinical applications.
Discussion
Chemokine ligands and receptors are hotly investigated
areas in biomedical research. The dissection of the bio-
logical roles of specific ligands and receptors has been
challenging because of the lack of selectivity in chemo-
kine ligand-receptor interactions [4]. This also greatly
limits the direct applications of natural chemokines in
the treatment of various diseases, such as HIV-1 infec-
tion. To overcome the limitation of natural chemokines,
various approaches have been taken to develop syn-
thetic chemokine analogs that have higher efficacy and
improved properties, such as the synthetic modifica-
tions of various chemokines conducted in a number of
elegant works by Clark-Lewis and colleagues [26–28],
and the recent success in the application of medicinal
chemistry to the generation of RANTES analogs re-
ported by Offord and colleagues [39]. Here, we demon-
strated a chemical biology approach to engineer de
novo selective properties into natural chemokines. The
effectiveness of this approach was illustrated by the
successful conversion of vMIP-II, the most nonspecific
and cross-reactive chemokine ligand known to date,
into highly specific ligands of CXCR4 or CCR5 through
modifying only a small N-terminal module of 10 residues.
Two representative SMM-chemokines, RCP168 and
RCP188, selective for CXCR4 and CCR5, respectively,
showed similar or significantly enhanced binding affini-
ties for their corresponding target receptors but drasti-
cally decreased or even completely abolished cross
binding activities for other receptors (Table 2).
In addition to high receptor selectivity, another impor-
tant biological property of these de novo designed li-
gands is signaling activity. As shown in Figures 3B and
5A–5B, RCP168 did not trigger either Ca2+ signaling or
receptor internalization, which is distinct from the natu-
ral ligand of CXCR4, SDF-1a. More interestingly,
RCP168 did not interfere with the Ca2+ signaling induced
by SDF-1a at its effective CXCR4 binding concentration
(5 nM), and only showed its effect at over 20-times
higher concentrations, such as 100 nM or 1 mM. We
also found that RCP168 potently inhibited HIV-1 entry,
in contrast to its much weaker activity in interfering
with SDF-1a signaling. These disparate inhibitory activ-
ity profiles of RCP168 in differentiating HIV-1 coreceptor
function versus the normal function of CXCR4 suggest
that this chemically engineered molecule has an inter-
esting and unique receptor binding mechanism, distinct
from that of SDF-1a, and may be used to selectively dis-
rupt the coreceptor activity of CXCR4. Furthermore, thedisparate activities of RCP168 may prove to be advanta-
geous in clinical applications, as RCP168 may not in-
duce unwanted Ca2+ signaling or interfere with SDF-1a
signaling important for the normal physiological func-
tions at the concentrations used for inhibiting HIV-1 in-
fection. In fact, the mechanistic basis for the disparate
activities of RCP168 was recently investigated and
shown by our mutational mapping analysis of binding
sites of RCP168 and other D-amino acid-containing
SMM-chemokines on CXCR4, revealing that RCP168
binding sites on CXCR4 overlap significantly with
HIV-1, but differ from SDF-1a [44].
As for the CCR5-specific SMM-chemokine, RCP188,
with its grafting of the N-terminal module of a CCR5 ag-
onist, MIP-1b, was able to mimic the signaling activity of
MIP-1b in activating Ca2+ release in CCR5-expressing
293 cells. This demonstrates that CCR5-selective bind-
ing and signaling activities are encoded in the imported
10 residue sequence from MIP-1b. In subsequent stud-
ies, we found that additional modifications on RCP188
or RCP168 can switch their signaling abilities from ago-
nists to antagonists or vice versa (unpublished data). As
such, we are able to apply the concept of SMM-chemo-
kines to generate specific agonists and antagonists for
either CCR5 or CXCR4, thus demonstrating that both
receptor selectivity and signaling property can be de-
signed at will into our synthetic ligands. While antago-
nists are often used for therapeutic applications, ago-
nists can also be of great interest as the molecular
probes to study a particular receptor-mediated signal-
ing pathway.
The results from the first generation of SMM-chemo-
kines reported here seem remarkable and promising,
considering that only the N-terminal 10 residue module
was modified, yet a significant effect on binding or
signaling selectivity was achieved. This illustrates the
simplicity and robustness of this method and, at the
same time, raises the possibility of its continued refine-
ment and sophistication. We note that, whereas the
deletion (as in RCP112) or modifications (as in RCP188
or RCP189) of the N-terminal 10 residue module can
completely abolish CXCR4 binding, the same molecules
retain residual, although significantly attenuated, bind-
ing activity for CCR5 and CCR2. This seems to imply
that, unlike CXCR4, other chemokine receptors, or at
least some receptors in the CCR subfamily, possess ad-
ditional, secondary functional modules, such as the
N-loop and/or the 300 loop, for interacting with their re-
ceptors [45, 46]. In this regard, we are extending the
present work to include these potential functional mod-
ules in our design and modification scheme. It may be
expected that continued development and optimization
of the SMM-chemokine strategy could achieve further
improved selectivity and biological profiles.
Specific SMM-chemokines for a designated chemo-
kine receptor can be potentially used in many areas of
basic research and therapeutic development. For in-
stance, one can use these SMM-chemokines as highly
specific molecular probes to study the biology of
chemokine receptors at the cellular level (i.e., to charac-
terize specific biological roles of a receptor in a physio-
logical or pathological process out of the complicated
and potentially overlapping receptor network). Also
the mechanism of receptor-ligand interactions at the
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various artificial changes in ligand probes and testing
how the receptor responds. This was demonstrated in
another of our studies [44], in which the SMM-chemo-
kines as reported here were used as chemical biology
probes to discover new functional sites on CXCR4,
important for the selective interactions with HIV-1 but
not with the normal physiological ligand of CXCR4,
SDF-1a, providing a basis for the development of more
selective antiviral therapies than the conventional drugs
that interrupt both pathological and physiological path-
ways. As chemokine receptors belong to the superfam-
ily of GPCRs, which represent the largest class of drug
targets and yet are still poorly understood in terms of
their structure-function relationship and ligand-receptor
interactions, the development of chemical biology
probes, such as SMM-chemokines, may have general
implications for the study of these important membrane
receptors. In addition to being valuable research tools,
receptor-selective SMM-chemokines are promising
leads for developing highly effective pharmaceutics.
For clinical applications, SMM-chemokines can be
highly desirable and advantageous for their greater se-
lectivity, higher potency, and reduced toxicity com-
pared with their natural counterparts. Most importantly,
not only was RCP168 found, in the study of drug-nonre-
sistant HIV-1 strains, to be comparable in efficacy to
some of the most well-known and commonly used
HIV-1 drugs, such as AZT, which targets HIV-1 reverse
transcriptase, but also RCP168, directed at an HIV-1
coreceptor expressed on the host cells was capable of
overcoming the drug resistance problem in drug-resis-
tant viral isolates, including AZT- and 3TC-resistant
HIV-1 isolates. This highlights the advantage of targeting
a nonviral protein over virus-encoded proteins in terms
of tackling the drug resistance issue. Since the drug re-
sistance is a major problem in the treatment of not only
AIDS but also other viral infections, the results shown in
this study may have broader implications for the devel-
opment of therapeutic strategies for diseases caused
by other viruses.
Significance
Chemokines and their receptors are implicated in
a wide range of human diseases, including acute
respiratory distress syndrome, allergic asthma, psori-
asis, arthritis, multiple sclerosis, cancer, atherosclero-
sis, and, most notably, AIDS. To enable the applica-
tions of chemokines as probes of receptor biology
and inhibitors of pathological processes, a major
problem with the lack of receptor selectivity of natural
chemokines must be overcome. Here, we report the
use of a chemical biology approach combining total
protein synthesis andmodularmodifications to gener-
ate a class of unnatural chemokines, termed SMM-
chemokines, that were chemically engineered with
high receptor selectivity and affinity, and reduced tox-
icity. A proof of the concept is shown by applying this
chemical strategy to transform vMIP-II, a very nonse-
lective chemokine, into new analogs with significantly
enhanced selectivity and potency for CXCR4 or CCR5,
two principal coreceptors for HIV-1 entry. In addition
to being valuable chemical probes of receptor biologyto study ligand binding and signaling mechanisms,
these molecules were shown to be promising leads
for the development of anti-HIV therapeutics, as they
were more potent in blocking HIV-1 entry and infection
and less toxic than natural chemokines. In particular,
the seemingly disparate inhibitory activity profiles of
RCP168 in blocking HIV-1 entry more potently than
CXCR4 normal function suggests a potentially inter-
esting receptor bindingmechanism of this compound,
which might be exploited as a basis for the develop-
ment of selective HIV-1 inhibitors. Finally, these inhib-
itory molecules were able to overcome the resistance
of HIV-1 strains against some of the most commonly
used anti-HIV drugs, demonstrating a strategy with
the advantage of targeting a nonviral protein over
virus-encoded proteins for tackling the drug resis-
tance issue, which is a major problem in the treatment
of AIDS and other viral infections.
Experimental Procedures
Total Chemical Synthesis of SMM-Chemokines
The automated stepwise incorporation of protected amino acids
was performed using a 433A peptide synthesizer (Applied Biosys-
tems, Foster City, CA) with a CLEAR amide resin (Peptides Inter-
national, Louisville, KY) as the solid support. Fmoc-chemistry was
employed for the synthesis. 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) and N-hydroxy-
benzotriazole (HOBt) were used as coupling reagents in the pres-
ence of diisopropylethylamine (DIEA). In certain coupling steps
with potentially slow reaction rates, double coupling followed by
capping of the unreacted amino functional groups was performed.
After incorporation of the 50th residue, 2% v/v of DMSO was intro-
duced to the solution to enhance the coupling reaction. After remov-
ing N-terminal Fmoc protection, the protein was cleaved from the
resin support by adding a cleavage cocktail comprised of phenol
(4% w/v), thioanisole (5% v/v), water (5% v/v), ethanedithiol (2.5%
v/v), triisopropylsilane (1.5% v/v), and trifluoroaceticacid (TFA,
82% v/v). The protein was precipitated by adding ice-cold tert-butyl
methyl ether and washed repeatedly in cold ether. The crude protein
was dissolved in 25% CH3CN in water containing 0.1% TFA before
being lyophilized, and it was then dissolved in water and purified
using semipreparative reverse-phase-high performance liquid chro-
matograph (RP-HPLC). Folding of the purified protein was per-
formed in 1 M guanidinium hydrochloride and 0.1 M trisma base at
pH 8.5 (1 mg protein/ml folding buffer), and was monitored by ana-
lytical RP-HPLC using a Vydac C-18 column (0.46 3 15 cm, 5 mm)
with a flow rate of 1 ml/min. Solvents used were: A, water with
0.1% TFA; and B, 20% water in CH3CN with 0.1% TFA; and a linear
gradient 30%–70% B over 30 min. Protein desaltation and purifica-
tion were then performed. The purified protein was characterized by
MALDI-TOF MS.
CD Spectroscopy
The spectra were recorded on the JASCO JA-710 spectropolarime-
ter over the range of 190–300 nm at room temperature with a 1.0 cm
pathway length quartz cuvette. The scan speed was 50 nm/s, with
the resolution of 1.0 nm. The spectra were signal-averaged four
times. The solvent baseline was subtracted from the spectra. The
spectra deconvolution was performed using the CDNN program
[47].
Materials
The radioiodinated SDF-1a and MIP-1b were purchased from Perkin-
Elmer Life Sciences (Boston, MA). Plasmid pcDNA3-CXCR4, plas-
mid pcDNA3-CCR5, antibodies 12G5 and 2D7, and human kidney
cell line 293 were obtained through the AIDS Research and Refer-
ence Reagent Program (Division of AIDS, NIAID, National Institutes
of Health, Bethesda, MD). Plasmid pcDNA3-CCR2 was a kind gift
from Dr. Israel Charo from the Gladstone Institute (University of Cal-
ifornia, San Francisco). Anti-human CCR2 antibody (a-CCR2) was
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77purchased from R&D system (Minneapolis, MN). Sup T1 cell line was
obtained through the European Collection of Cell Cultures (ECACC,
St. Louis, MO). Cell culture media and G418 were purchased from
CAMBREX (Walkersville, MD). While Dulbecco’s modified Eagle’s
medium (DMEM) plus 10% fetal bovine serum (FBS) and 5% penicil-
lin-streptomycin (P/S) was used to maintain 293 cells, RPMI 1640
plus 10% FBS and 5% P/S was used to culture Sup T1 cells.
Transfection of Adherent 293 Cells
Wild-type CXCR4, CCR5, or CCR2 were transfected into 293 cells
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. The selective medium containing
G418 (800 mg/ml) was used to isolate stably transfected cells that
were subsequently cloned from a single colony.
Flow Cytometry
Transfected 293 cells (5 3 105 cells/well) were washed with FACS
buffer (0.5% bovine serum albumin [BSA], 0.05% sodium azide in
PBS) and incubated with monoclonal antibody (MAb) 12G5, 2D7,
or a-CCR2 (10 mg/ml) for 30 min at 4ºC. After washing with FACS
buffer, the cells were incubated with 10 mg of fluorescein isothiocya-
nate (FITC)-conjugated goat anti-mouse IgG (Sigma, St. Louis, MO)
for 30 min at 4ºC. The cells were washed with FACS buffer and fixed
in the fixing buffer (2% paraformaldehyde in PBS) for 30 min at 4ºC
before being analyzed on the FACScan flow cytometer.
Competition Receptor Binding Assays
Using Labeled Chemokines
Ligand binding experiments were performed using a single concen-
tration (0.2 nM) of 125I-SDF-1a or 125I-MIP-1b in a final volume of 100
ml binding buffer (50 mM Hepes [pH 7.4], 1 mM CaCl2, 5 mM MgCl2,
0.1% BSA) containing 53 105 cells in 96-well plates in the presence
of various concentrations of unlabeled chemokines. Nonspecific
binding was determined by adding 150 nM unlabeled SDF-1a or
100 nM unlabeled vMIP-II. Samples were incubated for 60 min at
room temperature. The cells were washed with 200 ml binding buffer.
Bound ligands were determined by counting g emissions. The bind-
ing data were analyzed using the PRISM program (GraphPad Inc.,
San Diego, CA).
Competition Receptor Binding Assays with
Receptor-Specific Antibodies
Competition binding experiments were performed with a single con-
centration of 12G5 (50 ng/ml) or a-CCR2 (0.25 mg/ml) in a final volume
of 100 ml FACS buffer containing 53 105 cells in 96-well plates in the
presence of various concentrations of unlabeled chemokines. Sam-
ples were incubated on ice for 40 min. The cells were washed with
200 ml FACS buffer and stained with 10 mg FITC-conjugated goat
anti-mouse IgG for 30 min at 4ºC. As a negative control, cells were
stained only with the secondary antibody. The cells were washed
with FACS buffer and resuspended in 100 ml FACS buffer before be-
ing analyzed on the Wallac Victor2 1420 Multilabel counter (Turku,
Finland).
Intracellular Calcium Measurements
Sup T1 cells (107 cells/ml) were loaded with 2 mM fura-2/AM (Molec-
ular Probes, Eugene, OR) and 0.01% Pluronic F-127 (Sigma) in
Hank’s balanced salt saline (140 mM NaCl, 5 mM KCl, 10 mM Hepes
[pH 7.4], 1 mM CaCl2, 1 mM MgCl2, 1 mg/ml glucose, and 0.025%
BSA) for 20 min at room temperature. The cells were washed and re-
suspended in the same buffer to 106 cells/ml. Fura-2 fluorescence
was measured on the fluorescence spectrophotometer (ISA SPEX
FluoroMax-2; HORIBA Jobin Yvon, Inc., Edison, NJ) using excitation
wavelengths of 340 nm and 380 nm, and an emission wavelength of
510 nm.
Antiviral Assays
P4R5 cells were trypsinized, resuspended in complete DMEM (sup-
plemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomy-
cin, and 300 mg/ml glutamine) plus 1 mg/ml puromycin, and evenly
plated in 48-well plates at the density of 23 104 cells/well. The cells
were incubated at 37ºC, 5% CO2 overnight. Next day, the cells were
infected by adding 100 ml of virus at dilutions yielding 50–100 infec-
tious centers per well. The medium used for infection contained20 mg/ml DEAE-Dextran without puromycin. The cells were incu-
bated in the CO2 incubator for 2 hr. After incubation, 400 ml of com-
plete DMEM with different concentrations of SMM-chemokines or
control drugs (i.e., AZT, NVP, and 3TC) was added to each well be-
fore incubating the cells in the CO2 incubator for 2 days. Medium
from each well was removed before adding to each well 500 ml of
1% formaldehyde plus 0.2% glutaraldehyde in PBS. The cells were
fixed for 5 min and washed twice with PBS. Then, 300 ml of staining
solution (949 ml PBS, 20 ml of 0.2 M potassium ferrocyanide, 20 ml
of 0.2 M potassium ferricyanide, 1 ml of 2 M MgCl2, and 10 ml of
40 mg/ml X-GAL per ml) was added. The cells were incubated at
37ºC in a non-CO2 incubator for longer than 3 hr. The staining pro-
cess was stopped by removing the stain and washing twice with
PBS. The cells were allowed to dry completely. Blue cells in each
well were counted and compared with the number of cells in the
‘‘no drug’’ well to calculate the percent reduction.
Internalization Assays
Transfected 293 cells (3 3 105 cells/well) were plated onto 24-well
tissue culture plates pretreated with 0.01% poly-L-lysine (Sigma).
Nontransfected 293 cells were used as the background. Fixing the
cells for 5 min with 4% paraformaldehyde/PBS stopped the reac-
tions. After blocking the nonspecific binding with 1% BSA/PBS
and incubating the cells for 45 min, a MAb HA.11 (Covance Inc.,
Princeton, NJ) was added. The cells were washed with PBS and
reblocked with 1% BSA/PBS for 15 min. The cells were incubated
with goat anti-mouse-conjugated alkaline phosphate (Bio-Rad,
Richmond, CA) for 1 hr. The cells were washed with PBS before col-
orimetric alkaline phosphate substrate BCIP-NBT (Bio-Rad) was
added. The plate was continuously shaken until an adequate color
change occurred (w1 hr). The absorbance readings were taken
using the Wallac Victor2 1420 Multilabel counter.
MTS Toxicity Assays
Human blood was mixed with an equal volume of Iscove’s modified
Dulbecco’s medium (IMDM). The mixture was gently added onto the
top of Ficoll-Plaque Plus solution (Amersham Biosciences, Piscat-
away, NJ) and centrifuged at 3000 rpm for 30 min. The band contain-
ing the WBCs was collected, mixed with IMDM, and centrifuged at
1500 rpm for 8 min. After aspirating off the media, the WBCs were
washed with IMDM and centrifuged at 1200 rpm for another 5 min.
A total of 13 105 cells/well were plated in the 96-well plates and sub-
sequently incubated with SMM-chemokines for 24 hr. The number of
living cells was measured using CellTiter 96 aqueous nonradioactive
cell proliferation assays (Promega, Madison, WI), according to the
manufacturer’s instructions.
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